- Nxera Pharma Co. Ltd. announced that its partner Neurocrine Biosciences has received past FDA IND acceptance for a Phase 2 trial of NBI-1117567, an oral muscarinic M1-preferring agonist for Alzheimer's cognition, triggering a US$10,000,000 milestone payment to Nxera to be booked in Third Quarter Fiscal Year 2026.
- This IND milestone advances Neurocrine’s muscarinic M1/M4 franchise within a broad 2021 collaboration that could deliver up to US$2.60 billion in milestones plus royalties to Nxera.
- We’ll now examine how advancing NBI-1117567 into Phase 2 for Alzheimer’s cognition could influence Neurocrine’s neuroscience-focused investment narrative.
Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
Neurocrine Biosciences Investment Narrative Recap
To own Neurocrine, you need to believe its neuroscience focus can offset pricing pressure and dependence on INGREZZA and CRENESSITY with new, clinically meaningful launches. Advancing NBI-1117567 into Phase 2 for Alzheimer’s cognition reinforces the longer term diversification story, but it does not materially change the near term focus on CRENESSITY execution and payer dynamics, or the key risk from ongoing US drug pricing pressure and reimbursement complexity.
Among recent updates, the continued ramp of CRENESSITY for congenital adrenal hyperplasia is most relevant, since it highlights how Neurocrine is trying to reduce reliance on INGREZZA while adding another branded, access sensitive asset. Together with the muscarinic M1/M4 program, these developments frame a pipeline that could gradually rebalance revenue away from a single product, even as investors watch closely how much payer pushback and Medicare contracting may affect realized pricing on the core portfolio.
Yet while the pipeline looks broader, investors should also be aware that pricing pressure and payer scrutiny could still...
Read the full narrative on Neurocrine Biosciences (it's free!)
Neurocrine Biosciences' narrative projects $5.2 billion revenue and $1.4 billion earnings by 2029. This requires 15.6% yearly revenue growth and roughly a $700 million earnings increase from $705.5 million today.
Uncover how Neurocrine Biosciences' forecasts yield a $213.13 fair value, a 37% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$6.4 billion and earnings US$2.7 billion by 2029, so this fresh Alzheimer’s program progress may either reinforce that upbeat view or prompt a rethink if you see higher late stage R&D risk than they did.
Explore 3 other fair value estimates on Neurocrine Biosciences - why the stock might be worth just $211.72!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Neurocrine Biosciences research is our analysis highlighting 4 key rewards that could impact your investment decision.
- Our free Neurocrine Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neurocrine Biosciences' overall financial health at a glance.
Interested In Other Possibilities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
- Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com